Vaccinex, Inc. announced that Elizabeth Evans, PhD, Chief Operating Officer, is scheduled to present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit. The company’s SIGNAL-AD trial, a Phase 1/2 trial of pepinemab in patients diagnosed mild Alzheimer’s Disease (AD), is actively enrolling individuals living with AD. In cancer, the company is currently enrolling patients with recurrent or metastatic head and neck cancer in the Phase 1/2 KEYNOTE B84 trial which is evaluating the effectiveness of a combination of pepinemab with Merck’s KEYTRUDA® checkpoint inhibitor.